Financials in millions USD. Fiscal year is February - January.
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Revenue
73
48
47
42
38
48
Revenue Growth (YoY)
7%
2%
12%
11%
-21%
20%
Cost of Revenue
46
30
27
27
30
26
Gross Profit
27
17
19
14
7
22
Selling, General & Admin
69
41
38
50
45
30
Research & Development
19
10
14
15
14
8
Operating Expenses
75
45
55
69
57
40
Other Non Operating Income (Expenses)
0
0
2
--
--
--
Pretax Income
-59
-35
-38
-57
-59
-20
Income Tax Expense
0
0
0
0
0
0
Net Income
-59
-35
-31
-46
-21
-20
Net Income Growth
23%
13%
-33%
119%
5%
82%
Shares Outstanding (Diluted)
28.16
28.16
26.81
22.44
20.91
19.86
Shares Change (YoY)
5%
5%
19%
7%
5%
0%
EPS (Diluted)
-2.13
-1.26
-1.18
-2.06
-1.05
-1.05
EPS Growth
18%
7%
-43%
96%
0%
84%
Free Cash Flow
-34
-34
-28
-27
-8
-15
Free Cash Flow Per Share
--
--
--
--
--
--
Gross Margin
36.98%
35.41%
40.42%
33.33%
18.42%
45.83%
Operating Margin
-65.75%
-58.33%
-74.46%
-128.57%
-131.57%
-37.5%
Profit Margin
-80.82%
-72.91%
-65.95%
-109.52%
-55.26%
-41.66%
Free Cash Flow Margin
-46.57%
-70.83%
-59.57%
-64.28%
-21.05%
-31.25%
EBITDA
-41
-21
-25
-33
-35
-12
EBITDA Margin
-56.16%
-43.75%
-53.19%
-78.57%
-92.1%
-25%
D&A For EBITDA
7
7
10
21
15
6
EBIT
-48
-28
-35
-54
-50
-18
EBIT Margin
-65.75%
-58.33%
-74.46%
-128.57%
-131.57%
-37.5%
Effective Tax Rate
0%
0%
0%
0%
0%
0%
Follow-Up Questions
What are Crown LiquidationCo NV in liquidatie's key financial statements?
According to the latest financial statement (Form-10K), Crown LiquidationCo NV in liquidatie has a total asset of $77, Net loss of $-35
What are the key financial ratios for CNTGF?
Crown LiquidationCo NV in liquidatie's Current ratio is 0.75, has a Net margin is -72.91, sales per share of $1.7.
How is Crown LiquidationCo NV in liquidatie's revenue broken down by segment or geography?
Crown LiquidationCo NV in liquidatie largest revenue segment is Diagnostics, at a revenue of 36,470,354 in the most earnings release.For geography, United States is the primary market for Crown LiquidationCo NV in liquidatie, at a revenue of 16,037,269.
Is Crown LiquidationCo NV in liquidatie profitable?
no, according to the latest financial statements, Crown LiquidationCo NV in liquidatie has a net loss of $-35
Does Crown LiquidationCo NV in liquidatie have any liabilities?
yes, Crown LiquidationCo NV in liquidatie has liability of 102
How many outstanding shares for Crown LiquidationCo NV in liquidatie?
Crown LiquidationCo NV in liquidatie has a total outstanding shares of 29
Key Stats
Prev.Close
$0.1101
Open
$0.1101
Day's Range
$0.1101 - $0.1101
52 week range
$0.01 - $0.705
Volume
--
Avg.Volume
2.3K
Dividend yield
--
EPS (TTM)
-2.14
Market Cap
$3.0M
What is CNTGF?
Centogene NV is a commercial-stage company, which focuses on rare diseases that transform real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. The company is headquartered in Rostock, Mecklenburg-Vorpommern and currently employs 493 full-time employees. The company went IPO on 2019-11-07. The firm focuses on rare diseases, transforming clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. The firm's platform includes epidemiological, phenotypic, and genetic data reflecting a global population, as well as a biobank of blood samples from these patients. The firm's pharmaceutical segment provides a variety of services to its pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. The firm's Clinical Diagnostics segment provides targeted genetic sequencing and diagnostic services to patients through its distribution partners and customers, which are typically physicians, laboratories or hospitals.